US › Healthcare

Moleculin Biotech Inc (MBRX)

US · Healthcare · Biotechnology

$0.78+5.41%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-7.6M

EPS

$-1.40

EPS estimate

$-1.55

EPS came in at -1.40 against a street estimate of -1.55 — a beat of 9.7%.

Key statistics

Market cap

$13.9M

P/E

0.0

Forward P/E

0.0

P/B

1.22

Book value

$1.63

EPS (TTM)

$14.59

52-week high

$15.75

52-week low

$0.16

50-day MA

$1.21

200-day MA

$2.83

Beta

1.92

Analyst view

Analysts rate Moleculin Biotech Inc a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $12.00.

Shareholding

Insiders

6.41%

Institutions

8.57%

Largest institutional holders

Fund	Stake
Sabby Management LLC	0.39%
Geode Capital Management, LLC	0.17%
Vanguard Capital Management, LLC	0.07%
HRT FINANCIAL LLC	0.07%
Vanguard Fiduciary Trust Co	0.03%
Rockefeller Capital Management L.P.	0.02%
UBS Group AG	0.02%
Tower Research Capital LLC	0.01%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Moleculin Biotech Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.